TheraRadar
← Back
Data updated: Jun 28, 2026

ABIC

Pharma

ABIC is a pharmaceutical company focused on Oncology.

-
Since
4
Drugs
-
Trials
0
New Drugs (2yr)

ABIC's Key Drugs

ABIC's key approved drugs from the last 15 years (excludes generics, biosimilars and IV formulations).

No active drugs

ABIC's Recent FDA Approvals

New NDA/BLA approvals for ABIC over the last two years — novel drugs only, excluding generics and label supplements.

No recent approvals

ABIC's Therapeutic Areas

ABIC's approved drugs and pipeline span 1 therapeutic area, led by Oncology. Weighted by commercial stage — approved drugs count most, then late-stage trials.

Oncology 100%
1 drugs

ABIC's Top Competitors

ABIC's closest competitors by therapeutic-area and drug-target overlap include Pfizer, Novartis, and Merck. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.

ABIC Pipeline Snapshot

Active clinical trials for ABIC across all therapeutic areas, from ClinicalTrials.gov.

No active pipeline data available

Pro Intelligence Preview

Deep insights for investors and analysts

Revenue Insights

  • Top drug revenue breakdown
  • Drug-level revenue analysis

Trial Catalysts

  • Oncology pipeline focus
  • Phase 3 readout tracking

Patent Risk

  • Patent expiration timeline
  • Revenue at risk analysis

Compare Companies

  • Side-by-side pipeline analysis
  • Revenue & market share comparison
Unlock Full Intelligence

Revenue forecasts • Trial milestones • Patent risk modeling